Pfizer (PFE)

Dec 20, 2021Trade Ideas

Over the last few days, the number of Omicron cases has nearly doubled.

It’s now in 43 states, and in 90 countries. “The Centers for Disease Control and Prevention (CDC) estimates that Omicron accounts for at least 13 percent of all new cases in New York, which on Saturday recorded its highest ever single-day tally of new COVID-19 cases at 21,908, breaking the prior record of 21,027 set just one day earlier,” reports The Daily Mail.

Worse, Dr. Francis Collins, Director of the National Institutes of Health says the U.S. could see about a million infections a day. At the same time, according to NPR, it’s still too early to know how the virus will act in the U.S., as compared to previous variants.

At this point, no one knows when the pandemic chaos will end.

What we do know is that as long as the virus sticks around, some of the top potential winners could be virus stocks, such as Pfizer (PFE). While PFE is technically overvalued, it could see higher highs on the latest news. In fact, in pre-market, PFE is up more than $1.

In addition, according to MarketWatch, “Research shows only Pfizer/Moderna vaccines with booster stop omicron.”

To you and yours, have a happy, healthy holiday and New Year.

Sponsored Content

This page contains links to products not offered by MARKETARMOR.COM. In exchange for listing these links, we are likely to receive commission for purchases made through these links.

MARKETARMOR.COM is provided to you for informational purposes only and should not be construed as an offer to buy or sell a particular security or a solicitation of offers to buy or sell a particular security. MARKETARMOR.COM may make available certain information related to trading strategies and stock prices for educational and information purposes only; any information made available should not be construed as an endorsement, recommendation or sponsorship of any company or security.

We do not offer investment advice or advocate the purchase, holding or sale of any security or investment by any user of our materials or viewer of any of information videos. We do not provide any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular interment, security, or informational source. By visiting this site or using the training materials, you acknowledge and agree that any reliance upon the content or data available through MARKETARMOR.COM is at your own sole risk. You are strongly advised to use your own judgment, research, and consult a professional advisor.

The information is generic in nature and not targeted to individuals or individual circumstances. We offer our opinion and not specific advice. No professional relationship is formed by visiting this site, viewing its contents, or by purchasing a specific product or service we offer. No fiduciary relationship has been established, nor will one be established at any time.

Results are not typical. Trading securities may not be suitable for all users of this information. Trading stocks and investing in the stock market is inherently risky. You can lose money trading stocks. Do not invest money you cannot afford to lose. Before deciding to trade, you should ensure that you understand the risks involved and take into account your level of experience. You should seek independent advice, if necessary. You, the visitor to this site and user of our products and services, are solely responsible for any losses, financial or otherwise, as a result of trading stocks. Under all circumstances, you, and not MARKETARMOR.COM, assume the entire cost and all risks involved with trading any stock based on any information procured herein. Any views expressed on this site were prepared based upon the information available at the time such views were expressed. Changed or additional information could cause such views to change. The contributors of this site’s information may have a financial interest in many of the stocks discussed herein.